Methods of treating diabetes and other blood sugar disorders

• US 20050107318A1
• Filed: 11/17/2003
• Published: 05/19/2005
• Est. Priority Date: 11/17/2003
• Status: Abandoned Application

• Current Assignee: Genzyme Corporation (Sanofi )
• Original Assignee: Genzyme Corporation (Sanofi )
• Inventors: Parsons, Geoffrey, Wadsworth, Samuel, Armentano, Donna, Gregory, Richard J.
• Application Number:
  US10/715,976
• Publication Number:
  US 20050107318A1
• Time in Patent Office: Days
• US Class Current: 514/44.R
• CPC Class Codes: A61K 48/00 Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
• CPC Class Codes: A61K 48/005 characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
• CPC Class Codes: C12N 15/86 Viral vectors
• CPC Class Codes: C12N 2710/10343 viral genome or elements thereof as genetic vector
• CPC Class Codes: C12N 2830/002 inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
• CPC Class Codes: C12N 2830/85 mammalian

Abstract

Evidence is emerging that lipid accumulation in the liver and the muscle contributes to insulin resistance in type II diabetes and the metabolic syndrome (1). This has prompted an investigation of the relationship between lipid accumulation in the liver, serum triglyceride levels, and glucose disposal. These studies demonstrate that liver fat positively correlated to fasting triglyceride levels and negatively correlated to glucose diposal (2). Therefore, strategies to prevent lipid accumulation in liver would have therapeutic value for treatment of type II diabetes, metabolic syndrome and non-alcoholic fatty liver disease. The invention described here relates to continuous administration of GLP-1 or its analogs obtained by either gene or cell therapy that results in reduction serum triglycerides and reduction of lipid accumulation in the liver for treatment of type II diabetes, the metabolic syndrome or non-alcoholic fatty liver disease.

Claims

1. A method comprising administering to an individual an effective amount of a nucleic acid encoding a precursor glucagon-like peptide 1 (GLP-1) comprising mammalian GLP-I linked to a heterologous signal sequence, wherein the precursor GLP-1 is cleaved in vivo or ex vivo which results in generation of activated GLP-1 in the individual, wherein the activated GLP-1 reduces plasma triglyceride levels.

2. The method of claim 1 wherein the individual has a blood sugar defect selected from the group consisting of:

Type I diabetes and Type II diabetes.

3. The method of claim 1 wherein the nucleic acid encoding the precursor GLP-1 is administered in a viral vector.

4. The method of claim 1 wherein the nucleic acid encoding the precursor GLP-1 is administered as naked DNA.

5. A method comprising administering to an individual an effective amount of a nucleic acid encoding a precursor glucagon-like peptide 1 (GLP-1) comprising mammalian GLP-I linked to a heterologous signal sequence, wherein the precursor GLP-1 is cleaved in vivo or ex vivo which results in generation of activated GLP-1 in the individual, wherein the activated GLP-1 reduces lipid accumulation in an organ.

6. The method of claim 5 wherein the individual has a blood sugar defect selected from the group consisting of:

Type I diabetes and Type II diabetes.

7. The method of claim 5 wherein the nucleic acid encoding the precursor GLP-1 is administered in a viral vector.

8. The method of claim 5 wherein the nucleic acid encoding the precursor GLP-1 is administered as naked DNA.

9. A method comprising administering to an individual an effective amount of an isolated host cell comprising a nucleic acid encoding a precursor GLP-1 comprising mammalian GLP-1 linked to a heterologous signal sequence, wherein the precursor GLP-1 is produced and cleaved within the host cell which results in generation of activated GLP-1 in the individual, wherein the activated GLP-1 reduces lipid accumulation in an organ.

10. The method of claim 9 wherein the individual has a blood sugar defect selected from the group consisting of:

Type I diabetes and Type II diabetes.

11. The method of claim 9 wherein the nucleic acid encoding the precursor GLP-1 is administered in a viral vector.

12. The method of claim 9 wherein the nucleic acid encoding the precursor GLP-1 is administered as naked DNA.

13. A method comprising administering to an individual an effective amount of an isolated host cell comprising a nucleic acid encoding a precursor GLP-1 comprising mammalian GLP-1 linked to a heterologous signal sequence, wherein the precursor GLP-1 is produced and cleaved within the host cell which results in generation of activated GLP-1 in the individual, wherein the activated GLP-1 reduces reduces plasma triglyceride levels.

14. The method of claim 13 wherein the individual has a blood sugar defect selected from the group consisting of:

Type I diabetes and Type II diabetes.

15. The method of claim 13 wherein the nucleic acid encoding the precursor GLP-1 is administered in a viral vector.

16. The method of claim 13 wherein the nucleic acid encoding the precursor GLP-1 is administered as naked DNA.